Anaplastic Thyroid Carcinoma Following Radioactive Iodine Therapy for Graves’ Disease

다국어 초록 (Multilingual Abstract)

Radioactive iodine (RAI) therapy has been used as a treatment option for Graves’ disease, and it has been widely accepted to be safe. On the other hand, some evidence suggests that RAI therapy is possibly associated with a small increased risk of thyroid cancer. Herein, we report a rare case of anaplastic thyroid carcinoma (ATC) associated with Graves’ disease, following RAI treatment.
A 42-year-old woman had been diagnosed with Graves’ disease and although she was treated with an antithyroid drug, she remained in a hyperthyroid state, which led to two RAI treatments. More than 10 years later, the patient revisited our clinic due to hoarseness, dysphagia, and dyspnea, which had lasted for 2 months. Neck computed tomography suggested thyroid carcinoma and a lymph node biopsy showed metastatic papillary carcinoma. The patient underwent total thyroidectomy and was finally diagnosed as having an ATC. It is not clear if the occurrence of ATC reported here was influenced by the RAI therapy or alternatively,it may only represent the delayed recognition of a rare change in the natural history of Graves’ disease. Nevertheless, this report is worthwhile since it presents a very rare case of ATC that occurred eleven years after the RAI therapy for Graves’ disease.

참고문헌 (Reference)

1 Hoffmann S, "Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors" 89 : 6139-6145, 2004

2 DeGroot LJ, "Radioiodine and the immune system" 7 : 259-264, 1997

3 Sturgis CD, "Radioactive iodine-associated cytomorphologic alterations in thyroid follicular epithelium: is recognition possible in fine-needle aspiration specimens?" 21 : 207-210, 1999

4 Dobyns BM, "Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow- up study" 38 : 976-998, 1974

5 Lucignani G, "Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new?" 34 : 1504-1509, 2007

6 Belfiore A, "Graves’ disease, thyroid nodules and thyroid cancer" 55 : 711-718, 2001

7 Gossage AA, "Cases of carcinoma of thyroid following iodine- 131 therapy for hyperthyroidism" 41 : 8-12, 1984

8 Franklyn JA, "Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study" 353 : 2111-2115, 1999

9 Fujikawa M, "Anaplastic transformation of a papillary carcinoma of the thyroid in a patient with Graves’ disease with varied activity of thyrotropin receptor antibodies" 8 : 53-58, 1998

10 Ogawa M, "Anaplastic transformation from papillary thyroid carcinoma with increased serum CA19-9" 45 : 64-67, 2005

11 Majima T, "Anaplastic thyroid carcinoma associated with Graves’ disease" 52 : 551-557, 2005

12 Baker HW, "Anaplastic thyroid cancer twelve years after radioiodine therapy" 23 : 885-890, 1969

13 Rivkees SA, "An optimal treatment for pediatric Graves’ disease is radioiodine" 92 : 797-800, 2007